Plasma Cystatin C and Acute Kidney Injury

Acute Kidney Injury Clinical Trial

Official title:

Use of Cystatin C in Predicting AKI in Patients Undergone Cardiopulmonary Bypass Surgery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01652755
• Other study ID #: N-H-Y
• Status: Recruiting
• Phase: N/A
• First received: July 26, 2012
• Last updated: August 3, 2012
• Start date: April 2011
• Est. completion date: May 2013

Study information

• Verified date: August 2012
• Source: Jinhua Central Hospital
• Contact: Hongying Ni, MM
• Phone: 86
• Email: nihongying2[@]163.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

To evaluate the utility of plasma cystatin C(pCysC) as a predictive and diagnostic marker of acute kidney injury(AKI) in patients undergone cardiopulmonary bypass surgery.

Description:

This is a prospective AKI observational study in patients undergone cardiopulmonary bypass surgery. pCysC and plasma creatine will be measured at entry to ICU.AKI was defined as 50% increase in plasma creatine above baseline.The predictive and diagnostic performance of pCysC will be assessed from area under receiver operator characteristic curve(AUC) and odds ratio(OR).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: May 2013
• Est. primary completion date: May 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• patients with CPB and admitted to ICU

Exclusion Criteria:

• patients with the age >80 or <18 years

• with preexisting renal dysfunction

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Kidney Injury

Locations

Country	Name	City	State
China	Jinhua central hospital	Jinhua	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Jinhua Central Hospital

Country where clinical trial is conducted

China,